O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

Tizona Therapeutics Inc. promoted Christine O’Brien to CEO from COO, succeeding Scott Clarke. The promotion of O’Brien, a five-year veteran at Tizona, comes two months after Gilead Sciences Inc. (NASDAQ:GILD) acquired nearly half of the cancer company. Clarke took the CEO post at Trishula Therapeutics last month (see “Gilead Places Latest Bet on Cancer Immunosuppression”).

siRNA company Silence Therapeutics plc (LSE:SLN; NASDAQ:SLN) hired Mark Rothera as president and CEO. Iain Ross, who has been executive chairman since December, returns to his previous post of non-executive chairman. Rothera was previously CEO of fellow U.K. company Orchard Therapeutics plc (NASDAQ:ORTX), which he led to a NASDAQ listing...